Source: dvm 360
Zoetis is defending the safety of its osteoarthritis (OA) therapies for dogs and cats, Bedinvetmab (Librela) and Frunevetmab (Solensia), following reports of adverse effects. Pet owners claimed their animals experienced sickness instead of improvement. Despite these reports, Zoetis asserts that the majority of patients benefit from the drugs. Adverse events, though rare, have been acknowledged, and the company remains confident in the safety and efficacy of its products.
The FDA-approved medications target nerve growth factor (NGF) and have shown efficacy in pain relief and improved mobility. Despite social media attention on adverse reactions, experts emphasize the importance of continued study and pharmacovigilance. Veterinarians are encouraged to report any adverse effects to Zoetis for investigation and support.